These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22451252)

  • 41. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn.
    Kandulski A; Weigt J; Caro C; Jechorek D; Wex T; Malfertheiner P
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1075-81. PubMed ID: 25496815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
    Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
    J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antireflux surgery in the proton pump inhibitor era.
    Bulsiewicz WJ; Madanick RD
    Cleve Clin J Med; 2012 Apr; 79(4):273-81. PubMed ID: 22473727
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?
    de Bortoli N; Nacci A; Savarino E; Martinucci I; Bellini M; Fattori B; Ceccarelli L; Costa F; Mumolo MG; Ricchiuti A; Savarino V; Berrettini S; Marchi S
    World J Gastroenterol; 2012 Aug; 18(32):4363-70. PubMed ID: 22969200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
    Shimatani T; Sugimoto M; Nishino M; Adachi K; Furuta K; Ito M; Kurosawa S; Manabe N; Mannen K; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol Hepatol; 2012 May; 27(5):899-906. PubMed ID: 22098590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors.
    Zerbib F; Duriez A; Roman S; Capdepont M; Mion F
    Gut; 2008 Feb; 57(2):156-60. PubMed ID: 17951358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 24-hour ambulatory pH-metry in patients with refractory heartburn: a prospective study.
    Talaie R; Forootan M; Donboli K; Dadashzadeh N; Sadeghi A; Poorsaadat S; Moghimi B; Mohammad Alizadeh AH; Zali MR
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):11-5. PubMed ID: 19337627
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of the pH Value of Refluxate and Proximal Extent on Heartburn Perception in Patients with Proton Pump Inhibitor-Refractory Non-Erosive Reflux Disease.
    Abe Y; Koike T; Saito M; Okata T; Norita K; Kikuchi H; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Shimosegawa T; Masamune A
    Digestion; 2020; 101(4):375-381. PubMed ID: 31357199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Prevalence of Rome IV Nonerosive Esophageal Phenotypes in Children.
    Mahoney LB; Nurko S; Rosen R
    J Pediatr; 2017 Oct; 189():86-91. PubMed ID: 28711175
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
    Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
    Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid.
    Shapiro M; Green C; Bautista JM; Peru RL; Malagon IB; Corvo M; Risner-Adler S; Beeler JN; Tuchinsky I; Fass R
    Am J Gastroenterol; 2006 May; 101(5):1084-91. PubMed ID: 16573776
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reflux parameters as modified by laparoscopic fundoplication in 40 patients with heartburn/regurgitation persisting despite PPI therapy: a study using impedance-pH monitoring.
    Frazzoni M; Conigliaro R; Melotti G
    Dig Dis Sci; 2011 Apr; 56(4):1099-106. PubMed ID: 20737211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Unusual Cause of Regurgitation and Heartburn In a Patient With Fundoplication.
    Ferreira-Silva J; Morais R; Macedo G
    Gastroenterology; 2020 Sep; 159(3):847-848. PubMed ID: 32142776
    [No Abstract]   [Full Text] [Related]  

  • 54. Functional heartburn: what it is and how to treat it.
    Fass R
    Gastrointest Endosc Clin N Am; 2009 Jan; 19(1):23-33, v. PubMed ID: 19232278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional Chest Pain and Esophageal Hypersensitivity: A Clinical Approach.
    Bhardwaj R; Knotts R; Khan A
    Gastroenterol Clin North Am; 2021 Dec; 50(4):843-857. PubMed ID: 34717874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
    Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
    Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The added diagnostic value of postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with on-therapy impedance-pH monitoring.
    Frazzoni M; de Bortoli N; Frazzoni L; Tolone S; Furnari M; Martinucci I; Mirante VG; Marchi S; Savarino V; Savarino E
    Neurogastroenterol Motil; 2017 Mar; 29(3):. PubMed ID: 27620303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease.
    Woodland P; Al-Zinaty M; Yazaki E; Sifrim D
    Gut; 2013 Sep; 62(9):1256-61. PubMed ID: 22722617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
    Lee KJ; Kwon HC; Cheong JY; Cho SW
    Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.